Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hazard Ratio01:12

Hazard Ratio

111
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
111
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177
Actuarial Approach01:20

Actuarial Approach

74
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
74
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

533
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
533
Truncation in Survival Analysis01:09

Truncation in Survival Analysis

194
Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
194

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do home modifications reduce caregiver burden? A cross-sectional analysis of factors associated with caregiver burden and resilience in Hong Kong.

Innovation in aging·2026
Same author

Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study.

Frontiers in neurology·2026
Same author

A Generative AI Framework for Pharmacokinetic Clinical Study Report Authoring.

Clinical and translational science·2026
Same author

Allelic variation in the thioredoxin TRX-M4 influences carbon partitioning to control soluble sugar content in apple fruit.

Plant communications·2026
Same author

Automated Measurement of Depigmentation Extent with a New AI Tool Applied to the Example of Vitiligo.

Dermatology and therapy·2026
Same author

Early Maturation of Functional Connectivity within Dorsal Brain Networks.

Brain connectivity·2026

Related Experiment Video

Updated: Jun 25, 2025

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
03:14

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

544

Using large language models for safety-related table summarization in clinical study reports.

Rogier Landman1, Sean P Healey1, Vittorio Loprinzo1

  • 1Pfizer Research and Development, New York, NY 10001, United States.

JAMIA Open
|May 31, 2024
PubMed
Summary

Large language models (LLMs) show promise for automating clinical trial documentation, specifically summarizing safety tables in clinical study reports (CSRs). While effective, human oversight remains crucial for optimizing LLM performance in this domain.

Keywords:
GPT-3.5clinical trialsgenerative artificial intelligencelarge language modelsnatural language processingregulatory documentstext summarization

More Related Videos

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

15.9K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K

Related Experiment Videos

Last Updated: Jun 25, 2025

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
03:14

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

544
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

15.9K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K

Area of Science:

  • Clinical Documentation Automation
  • Artificial Intelligence in Healthcare
  • Natural Language Processing

Background:

  • Clinical trial documentation, particularly safety table summarization in Clinical Study Reports (CSRs), presents a complex challenge.
  • Large Language Models (LLMs) offer a potential solution for automating the generation of these structured documents.
  • A competitive challenge was organized to explore LLM capabilities in this area.

Observation:

  • Multiple teams utilized prompt engineering with Generative Pre-trained Transformer (GPT) models to generate safety table summaries.
  • An evaluation framework combining automated metrics and expert reviews assessed the quality of AI-generated documents.
  • Performance varied across different LLM solutions, with notable differences in factual accuracy and conciseness.

Findings:

  • LLMs demonstrate significant potential for automating the summarization of safety tables within CSRs.
  • Factual accuracy and lean writing were identified as key areas where LLM performance varied.
  • Prompt engineering with GPT models was a common approach among participating teams.

Implications:

  • The results highlight the feasibility of using LLMs for clinical trial documentation automation.
  • Areas for improvement include enhancing table data ingestion, incorporating contextual information, and model fine-tuning.
  • Continued research and human involvement are essential for maximizing the benefits of LLMs in clinical reporting.